Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IMRN - Immuron Limited - ADR


IEX Last Trade
2.83
0.170   6.007%

Share volume: 3,990
Last Updated: Fri 30 Aug 2024 04:38:31 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$2.66
0.17
6.39%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-0.74%
1 Month
6.80%
3 Months
15.09%
6 Months
54.34%
1 Year
32.18%
2 Year
6.59%
Key data
Stock price
$2.83
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.48 - $5.96
52 WEEK CHANGE
$0.44
MARKET CAP 
15.219 M
YIELD 
N/A
SHARES OUTSTANDING 
5.700 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,346
AVERAGE 30 VOLUME 
$3,817
Company detail
CEO:
Region: US
Website: https://www.immuron.com.au
Employees: 11
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

immuron ltd is a publicly listed australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (nash) diabetes, colitis, arthritis, inflammatory bowel diseases (ibd), irritable bowel syndrome (ibs), liver fibrosis and other chronic disorders in which the immune system plays a key role in thier pathogenesis. these disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile. immuron has one marketed product, which provides proof of concept for its oral immune technology platform, and a pipeline of products at various stages of cl

Recent news